PEAR Therapeutics

PEAR Therapeutics

Pear Therapeutics is the leader in FDA-cleared Prescription Digital Therapeutics. The company integrates clinically-validated software applications with previously approved pharmaceuticals.

About PEAR Therapeutics

Pear Therapeutics is the leader in FDA-cleared Prescription Digital Therapeutics. The company integrates clinically-validated software applications with previously approved pharmaceuticals and treatment paradigms to provide better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers. Pear’s lead product, reSET®, is an FDA-cleared 12-week interval prescription therapy for Substance Use Disorder (SUD) to be used as an adjunct to standard, outpatient treatment. Pear’s product development pipeline includes reSET®-O™ for opioid use disorder (OUD) and additional prescription digital therapeutics in schizophrenia (Thrive™), combat posttraumatic stress disorder (reCALL™), general anxiety disorder (reVIVE™), pain, major depressive disorder, and insomnia. For more details, please see www.peartherapeutics.com.

Team

Funding

INVESTOR
STAGE
AMOUNT
DATE

Singapore

See all investors
Round: Series B
Round Size: US$50M
Date: Jan 2018